|
|
News Breaks | | | | November 9, 2012 | | 07:11 EDT |  | POZN | POZEN upgraded to Strong Buy from Buy at Ascendiant Capital
Ascendiant Capital upgraded POZEN with an $8.25 price target citing the recent pullback in shares. | |
|
News For POZN From The Last 14 Days Check below for free stories on POZN the last two weeks. |
|
|
| May 21, 2013 | | 07:44 EDT |  | POZN | POZEN says PA32540 resulted in fewer gastric ulcers in trial
POZEN presented the Abstract, Prevalence of Gastric Ulcers in Aspirin Users/Does the Presence of Erosions Foreshadow Ulcer Development, from a post-hoc analysis of Phase 3 data from the investigational compound PA32540. The analysis of patients screened for the Phase 3 studies demonstrated that at any time point, over 4% of subjects on low dose aspirin for cardiovascular and cerebrovascular disease have endoscopic gastric ulcers that go undetected. In addition, the analysis demonstrated that even the presence of small lesions known as endoscopic gastric erosions in aspirin-users was associated with a 2-fold increased risk of future development of endoscopic gastric ulcers. In patients with gastric erosions at baseline, PA32540, a coordinated-delivery tablet combining immediate-release omeprazole, layered around a pH-sensitive coating of a 325 mg ASA core, resulted in significantly fewer gastric ulcers at six months vs. EC-ASA. These data were presented for the first time at Digestive Disease Week 2013 on May 20. | |
|
|
|
|
|
|
